These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26463904)

  • 61. Use of very low-dose naltrexone during opiate detoxification.
    Mannelli P; Gottheil E; Buonanno A; De Risio S
    J Addict Dis; 2003; 22(2):63-70. PubMed ID: 12703669
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression.
    Schürks M; Overlack M; Bonnet U
    Pharmacopsychiatry; 2005 Mar; 38(2):100-2. PubMed ID: 15744636
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Interactions between naltrexone, an opioid antagonist, and opioids administered during general anesthesia].
    Tesson B; Bigot-Viale A; Vigue JP; Pierrot M; Granry JC
    Ann Fr Anesth Reanim; 1999 Feb; 18(2):230-2. PubMed ID: 10207596
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nalmefene: a review of its use in the treatment of alcohol dependence.
    Keating GM
    CNS Drugs; 2013 Sep; 27(9):761-72. PubMed ID: 23949908
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of ultra-rapid opiate detoxification on withdrawal syndrome.
    Safari F; Mottaghi K; Malek S; Salimi A
    J Addict Dis; 2010 Oct; 29(4):449-54. PubMed ID: 20924880
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
    Holtzman SG
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nalmefene for the treatment of alcohol dependence: a current update.
    Soyka M
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):675-84. PubMed ID: 24246244
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.
    Arias AJ; Armeli S; Gelernter J; Covault J; Kallio A; Karhuvaara S; Koivisto T; Mäkelä R; Kranzler HR
    Alcohol Clin Exp Res; 2008 Jul; 32(7):1159-66. PubMed ID: 18537939
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
    Ingman K; Hagelberg N; Aalto S; Någren K; Juhakoski A; Karhuvaara S; Kallio A; Oikonen V; Hietala J; Scheinin H
    Neuropsychopharmacology; 2005 Dec; 30(12):2245-53. PubMed ID: 15956985
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acute opioid withdrawal on accidental injection of naltrexone.
    Yeo M; Campbell V; Bonomo Y; Sawyer SM
    J Paediatr Child Health; 2003; 39(4):315-7. PubMed ID: 12755943
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse.
    O'Malley SS
    Alcohol Alcohol; 1996 Mar; 31 Suppl 1():77-81. PubMed ID: 8737005
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
    Laramée P; Millier A; Rahhali N; Cristeau O; Aballéa S; François C; Chalem Y; Toumi M; Rehm J
    Appl Health Econ Health Policy; 2016 Aug; 14(4):493-505. PubMed ID: 27283839
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nalmefene and its use in alcohol dependence.
    Gual A; Bruguera P; López-Pelayo H
    Drugs Today (Barc); 2014 May; 50(5):347-55. PubMed ID: 24918835
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Severe central sleep apnoea associated with nalmefene: a case report.
    Khouri C; Arbib F; Revol B; Pepin JL; Tamisier R
    Br J Clin Pharmacol; 2018 May; 84(5):1075-1076. PubMed ID: 29479731
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report.
    Martín-Blanco A; Patrizi B; Soler J; Gasol X; Elices M; Gasol M; Carmona C; Pascual JC
    Int Clin Psychopharmacol; 2017 Jul; 32(4):231-234. PubMed ID: 28181957
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Potential danger of nalmefene use in the emergency department.
    Gaeta TJ; Capodano RJ; Spevack TA
    Ann Emerg Med; 1997 Jan; 29(1):193-4. PubMed ID: 8998112
    [No Abstract]   [Full Text] [Related]  

  • 77. Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject.
    Salvato FR; Mason BJ
    Alcohol Clin Exp Res; 1994 Oct; 18(5):1187-9. PubMed ID: 7847604
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.
    Aubin HJ; Reimer J; Nutt DJ; Bladström A; Torup L; François C; Chick J
    Eur Addict Res; 2015; 21(3):160-168. PubMed ID: 25832297
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Case of Delirium and Rhabdomyolysis in Severe Iatrogenic Opioid Withdrawal.
    Hanna J; Swetter S
    Psychosomatics; 2018; 59(4):405-407. PubMed ID: 29325983
    [No Abstract]   [Full Text] [Related]  

  • 80. Safety of nalmefene for the treatment of alcohol use disorder: an update.
    López-Pelayo H; Zuluaga P; Caballeria E; Van den Brink W; Mann K; Gual A
    Expert Opin Drug Saf; 2020 Jan; 19(1):9-17. PubMed ID: 31868031
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.